vector, 4D-C102, demonstrates superior performance compared to commonly used AAV1,
AAV8, and AAV9 -
product candidate, 4D-310, is on track for anticipated clinical trial
initiation in 2020 -
Superior transduction of 4DMT’s novel vector, 4D-C102,
Company adds manufacturing and quality expertise and broad financial, operational and legal experience with the appointments of Fred Kamal, PhD as chief technical officer and head of regulatory and quality and of August Moretti as chief financial officerCompany announces ...
Emeryville, CA – December 6, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced a research and development collaboration with the Casey Eye Institute ...